![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/08/13/2929044/0/en/Entrada-Therapeutics-Reports-Second-Quarter-2024-Financial-Results.html
https://www.globenewswire.com/news-release/2024/06/24/2902879/0/en/Entrada-Therapeutics-Announces-100-Million-Registered-Direct-Offering.html
https://www.globenewswire.com/news-release/2024/06/24/2902819/0/en/Entrada-Therapeutics-Reports-Positive-Preliminary-Data-in-Healthy-Volunteers-from-Phase-1-ENTR-601-44-101-Trial-for-Duchenne-Muscular-Dystrophy.html
https://www.globenewswire.com/news-release/2024/06/03/2892092/0/en/Entrada-Therapeutics-to-Present-at-Goldman-Sachs-45th-Annual-Global-Healthcare-Conference.html
https://www.globenewswire.com/news-release/2024/05/16/2883259/0/en/Entrada-Therapeutics-to-Present-at-H-C-Wainwright-2nd-Annual-BioConnect-Investor-Conference-at-NASDAQ.html
https://www.globenewswire.com/news-release/2024/05/07/2876553/0/en/Entrada-Therapeutics-Reports-First-Quarter-2024-Financial-Results.html
https://www.globenewswire.com//news-release/2024/03/13/2845281/0/en/Entrada-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html
https://www.globenewswire.com//news-release/2024/02/07/2825062/0/en/Entrada-Therapeutics-to-Present-at-Upcoming-Investor-Conferences.html
https://www.globenewswire.com//news-release/2024/01/03/2803161/0/en/Entrada-Therapeutics-Promotes-Nathan-J-Dowden-to-President.html
https://www.fiercebiotech.com/biotech/fda-rebuffs-entradas-attempt-get-year-long-hold-dmd-drug-lifted